EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orchestra BioMed Holdings's Enterprise Value is $88.73 Mil.
Orchestra BioMed Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.21 Mil. Therefore, Orchestra BioMed Holdings's EV-to-FCF for today is -1.92.
The historical rank and industry rank for Orchestra BioMed Holdings's EV-to-FCF or its related term are showing as below:
OBIO'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.99 Med: -3.54 Max: -1.48
Current: -2.03
During the past 4 years, the highest EV-to-FCF of Orchestra BioMed Holdings was -1.48. The lowest was -13.99. And the median was -3.54.
OBIO's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 6.23
vs OBIO: -2.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Orchestra BioMed Holdings's EV-to-FCF
For the Biotechnology subindustry, Orchestra BioMed Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's EV-to-FCF falls into.
Orchestra BioMed Holdings's current Enterprise Value is $88.73 Mil.
Orchestra BioMed Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Orchestra BioMed Holdings's PE Ratio for today is calculated as:
Orchestra BioMed Holdings's share price for today is $4.94.
Orchestra BioMed Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Orchestra BioMed Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Orchestra BioMed Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OBIO has been successfully added to your 